These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10650795)

  • 1. Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease.
    Villani F; Dell'Oca I; De Maria P; Viola G; Di Russo A; Viviani S; Bonfante V
    Anticancer Res; 1999; 19(5C):4475-9. PubMed ID: 10650795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease.
    Villani F; Busia A; Villani M; Vismara C; Viviani S; Bonfante V
    Tumori; 2008; 94(6):803-8. PubMed ID: 19267096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose chemotherapy for Hodgkin's disease.
    Villani F; Viola G; Vismara C; Laffranchi A; Di Russo A; Viviani S; Bonfante V
    Anticancer Res; 2002; 22(4):2403-8. PubMed ID: 12174934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
    Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late pulmonary toxicity after treatment for Hodgkin's disease.
    Villani F; De Maria P; Bonfante V; Viviani S; Laffranchi A; Dell'oca I; Dirusso A; Zanini M
    Anticancer Res; 1997; 17(6D):4739-42. PubMed ID: 9494599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
    Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
    Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
    Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement.
    Anselmo AP; Bove M; Cartoni C; Damico C; Maurizi Enrici R; Falchetto Osti M; Biagini C
    Haematologica; 1992; 77(2):177-9. PubMed ID: 1383107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.
    Hirsch A; Vander Els N; Straus DJ; Gomez EG; Leung D; Portlock CS; Yahalom J
    J Clin Oncol; 1996 Apr; 14(4):1297-305. PubMed ID: 8648387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
    Lipton JH; Gospodarowicz M; Reingold S
    Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.